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Abstract 
Background: Infectious diseases are still a leading cause of death and, with the emergence of drug resistance, pose 
a great threat to human health. New drugs and strategies are thus urgently needed to improve treatment efficacy and 
limit drug‑associated side effects. Nanotechnology‑based drug delivery systems are promising approaches, offering 
hope in the fight against drug resistant bacteria. However, how nanocarriers influence the response of innate immune 
cells to bacterial infection is mostly unknown.
Results: Here, we used Mycobacterium tuberculosis as a model of bacterial infection to examine the impact of man‑
nose functionalization of chitosan nanocarriers (CS‑NCs) on the human macrophage response. Both ungrafted and 
grafted CS‑NCs were similarly internalized by macrophages, via an actin cytoskeleton‑dependent process. Although 
tri‑mannose ligands did not modify the capacity of CS‑NCs to escape lysosomal degradation, they profoundly remod‑
eled the response of M. tuberculosis‑infected macrophages. mRNA sequencing showed nearly 900 genes to be differ‑
entially expressed due to tri‑mannose grafting. Unexpectedly, the set of modulated genes was enriched for pathways 
involved in cell metabolism, particularly oxidative phosphorylation and sugar metabolism.
Conclusions: The ability to modulate cell metabolism by grafting ligands at the surface of nanoparticles may thus be 
a promising strategy to reprogram immune cells and improve the efficacy of encapsulated drugs.
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Background
Bacterial infection is a major cause of chronic infec-
tions and mortality. Tuberculosis (TB), which is caused 
by Mycobacterium tuberculosis, is the deadliest disease 
caused by a single infectious agent, ahead of HIV/AIDS 
and malaria. According to the most recent WHO report 
[1], there were 10.4 million TB cases in 2016 and the dis-
ease killed 1.7 million individuals. Even more serious is 
the worldwide emergence of drug-resistant bacteria, 
endangering the efficacy of antibiotics. Each year in the 
United States and Europe, 23,000 and 25,000 people, 
respectively, die as a direct result of antimicrobial resist-
ance [2, 3]. The ability to cure multidrug resistant bacte-
rial infections is more difficult, requiring treatment with 
more toxic and costly drugs, often with limited success. 
Hepatotoxicity, liver injury, skin reactions, and gastro-
intestinal and neurological disorders have frequently 
been observed as adverse effects. New strategies are thus 
urgently needed against resistant strains to shorten the 
duration of treatment and limit drug side-effects.
Nanoparticles are an attractive approach to increase the 
efficacy of antibiotics and decrease drug side-effects [4, 
5]. Nanocarriers (NCs) are a broad family of submicron 
structures with unique size-dependent features, including 
high stability, efficient drug loading, controlled-release, 
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and cell-targeting [6]. Previous studies have shown effec-
tive internalization of NCs by phagocytes, in particular 
macrophages ( Mφs ), thus allowing delivering of antibi-
otics [7], antigens for vaccination [8], or contrast agents 
for biomedical imaging [9]. For example, liposomes and 
solid lipid nanoparticles have been shown to improve the 
activity of antibiotics, such as amikacin and vancomy-
cin, against Pseudomonas aeruginosa and Staphylococcus 
aureus [10, 11]. Lipid NCs loaded with rifampicin, one of 
the first-line TB drugs, exhibit higher lung and Mφ-spe-
cific targeting than the free drug in  vivo [12, 13]. Poly-
meric nanoparticles composed of natural or synthetic 
polymers, such as chitosan and poly(lactide-co-glycolide) 
acid (PLGA), have shown good drug encapsulation and 
delivery [14–16]. Moreover, it was shown that nanopar-
ticles are able to effectively target granuloma-like struc-
tures using transparent zebrafish embryos infected with 
Mycobacterium marinum as a model of TB infection, 
thus improving embryo survival and lowering bacterial 
load [7]. NCs have also been recently used to improve 
BCG-vaccine immunogenicity by enhancing the innate 
immune response to BCG vaccination [17].
Numerous NCs have been developed in the past dec-
ades using several experimental approaches. One of the 
best strategies to produce and stabilize NCs consists of 
using aqueous- or oil-core nanocapsules surrounded by 
a polymeric coating that can be synthetic, such as PLGA, 
or natural, such as chitosan. Chitosan coating provides 
several advantages, such as biocompatibility, biodegra-
dability, and functional groups for biofunctionalization 
for cell targeting, making chitosan NCs (CS-NCs) an 
excellent delivery system. We previously reported the 
production of CS-NCs with improved stability, by nano-
emulsion with a chitosan hydrogel coating, and their 
use as an efficient drug delivery system for the antimi-
crobial agent bedaquiline [18, 19]. Here, we performed 
an in-depth study of the interactions of CS-NCs with 
human monocyte-derived Mφs , resting or infected with 
M. tuberculosis, as a model of bacterial infection. mRNA 
sequencing allowed us to identify genes and pathways 
affected by CS-NC treatment. CS-NCs regulated the 
expression of relatively few genes but, surprisingly, the 
addition of tri-mannose carbohydrates to CS-NCs (CS-
NCs-tri) profoundly remodeled the response of M. tuber-
culosis-infected cells.
Results and discussion
Chitosan NCs are efficiently internalized by Mφs in an actin 
cytoskeleton‑dependent manner
We first evaluated the capacity of human Mφs to inter-
nalize CS-NCs. Monocyte-derived Mφs were incu-
bated for 4  h with Nile Red-labelled CS-NCs. After 
extensive washing, we quantitatively assessed particle 
internalization by FACS. Mφs efficiently internalized CS-
NCs in a dose- and time-dependent manner (Fig. 1a, b). 
The uptake of NCs was very fast. We observed Nile Red 
positive-Mφs in as little as 15 min (data not shown). We 
analyzed CS-NC-treated Mφs by confocal microscopy 
after 1, 4, and 18 h of incubation to discriminate between 
binding of the NCs to the cell surface and their inter-
nalization. The NCs were localized intracellularly and 
accumulated with time (Fig.  1c). We next evaluated the 
capacity of other cell types, namely lung epithelial cells 
(A549) and hepatocytes (HepG2), to internalize CS-NCs. 
Hepatocytes internalized a smaller number of CS-NCs 
than Mφs (0.6-fold less), whereas the uptake by epithelial 
cells was similar (Fig. 1d). These results confirm previous 
studies showing efficient internalization of CS-NCs by 
several cell types, including epithelial cells, hepatocytes, 
fibroblasts, and Mφs [20].
We next treated Mφs with inhibitors of phagocytosis, 
macropinocytosis, clathrin-mediated endocytosis, and 
caveolae-mediated endocytosis to decipher the molecu-
lar mechanisms involved in NC internalization [21]. 
Cytochalasin D inhibits phagocytosis by preventing actin 
polymerization [22]. Chlorpromazine reduces invagina-
tion via clathrin-mediated endocytosis by depleting the 
plasma membrane of clathrin and adaptor proteins and 
sequestering them on intracellular vesicles [23]. Nys-
tatin interferes with caveolae-mediated endocytosis by 
increasing membrane fluidity via the depletion of cho-
lesterol and reducing the formation of lipid caveolar 
rafts [24]. Colchicine decreases microtubule polymeri-
zation, thus inhibiting micropinocytosis [25]. Cells were 
incubated with fluorescent NCs for 2 h, with or without 
the inhibitors, and the internalization of NCs quanti-
fied by flow cytometry. Only cytochalasin D significantly 
decreased the uptake of CS-NCs (Fig. 1e). These results 
show that CS-NCs enter Mφs via an actin cytoskeleton-
dependent process, most likely phagocytosis.
Chitosan NCs escape degradation in lysosomes
Mφs are professional phagocytes that are highly special-
ized to engulf and eliminate dead cells, cellular debris, 
and foreign particles, including bacteria and viruses [26]. 
We used transmission electron microscopy (TEM) and 
confocal microscopy to follow the fate of intracellular 
NCs inside this cell type. CS-NCs were easily detectable 
inside Mφs after 1 h of incubation (data not shown). Sur-
prisingly, the CS-NCs were still present after 18 h of incu-
bation and were not degraded. Some even fused together, 
resulting in large NCs (Fig.  2a). This suggests that CS-
NCs can resist lysosomal degradation and/or escape 
from the endosomal pathway. We could not detect mem-
branes surrounding the CS-NCs, favoring the second 
hypothesis. We strengthened these results by incubating 
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Mφs with fluorescent CS-NCs and LysoTracker Red 
DND-99, a red fluorescent dye that stains acidic com-
partments, mainly lysosomes, in live cells, and analyzed 
their intracellular localization by confocal microscopy. 
Most CS-NCs did not colocalize with acidic compart-
ments after 18 h of incubation (Fig. 2b, Pearson correla-
tion coefficient < 0.6, Fig.  2c). Thus, we did not observe 
the formation of new lysosomal compartments upon 
0
35
70
105
140 Nys Cyto D
Col Chlo
**
%
 U
pt
ak
e
eb
0
20
40
60
80
0 1 4 18
Time (hours)
M
FI
 (x
 1
03
)
d Mφ
A549
HepG2
0
20
40
60
M
FI
 (x
 1
03
)
***
c
a
0
20
40
60
C
el
l c
ou
nt
100
80
102 103 104
Fluorescence intensity
control
10 µg/ml
50 µg/ml
100 µg/ml
1h 4h 18h
Fig. 1 Cellular uptake of chitosan NCs. a Mφs were incubated for 4 h with 10, 50, and 100 µg/ml Nile‑Red‑labelled CS‑NCs. Particle internalization 
was assessed by FACS and the results expressed as the mean fluorescence intensity (MFI). b Mφs were cultured for 1, 4, or 18 h in the presence of 
100 µg/ml fluorescent CS‑NCs and particle internalization was quantitatively assessed by FACS. c Mφs were treated with 100 µg/ml fluorescent 
CS‑NCs (red) for 1, 4, or 18 h and NC internalization visualized by confocal microscopy. DAPI (blue) was used to visualize nuclei. d 100 µg/ml 
Nile‑Red‑labelled CS‑NC were incubated for 4 h with Mφs , A549 epithelial cells, or HepG2 hepatocytes. NP uptake was quantitatively analyzed 
by FACS. e Mφs were incubated with 100 µg/ml fluorescent CS‑NCs for 2 h with or without the pharmacological inhibitors nystatin, colchicine, 
cytochalasin D, or chlorpromazine. NC uptake was analyzed as previously described. Error bars represent the mean ± SD and significant differences 
between treatments are indicated by an asterisk, in which **p < 0.01 and ***p < 0.001
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treatment with CS-NCs. We quantified the intensity of 
the LysoTracker staining by flow cytometry. There was 
no difference between untreated cells and cells incubated 
with CS-NCs, whereas incubation with latex beads (used 
as a positive control) induced an increase of LysoTracker 
staining (Fig. 2d). Our results are consistent with those of 
previous studies. Indeed, it has been shown that polyeth-
ylenimine and chitosan can directly overcome lysosomal 
sequestration by membrane destabilization [27–29] 
or through a proton sponge effect [30–33]. NCs may 
enhance endosomal Cl-accumulation and osmotic swell-
ing, leading to vesicle rupture.
Effects of NCs on the Mφ response
The phagocytosis of particles by Mφs modulates the 
expression of many genes, the number and extent 
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Fig. 2 Intracellular localization of chitosan NCs. a Mφs were cultured for 18 h in the presence of 100 µg/ml CS‑NCs and intracellular visualization 
assessed by TEM. Yellow arrows: CS‑NCs, Red arrows: NCs fusion. b Mφs were incubated with 100 µg/ml DiD‑labelled CS‑NCs (green) for 18 h, 
co‑stained with LysoTracker (red) and DAPI (blue), and visualized by confocal microscopy. c Pearson correlation coefficient between CS‑NCs and 
acidic compartments (Lysotracker positive). Each dot represents one single cell (n = 98). Error bars represent the mean ± SD. d Mφs were exposed to 
100 µg/ml CS‑NCs or latex beads for 18 h and incubated with Lysotracker Red. The intensity of the lysotracker staining was then quantified by FACS. 
Results are expressed as the mean fluorescence intensity (MFI). Significant differences between treatments and untreated controls are indicated by 
an asterisk, in which *p < 0.05. Error bars represent the mean ± SD
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depending on the receptors involved. In the context of 
NCs, it is important to decipher the impact of CS-NC 
internalization on the cell transcriptome to identify 
potential side effects. Indeed, it has been shown that 
NCs can regulate the expression of cell-cycle-related 
genes, modulate inflammation, and up-regulate the 
stress response [34–36]. We evaluated the host response 
to CS-NCs by comparing the transcriptional profiles of 
untreated Mφs (control) with those incubated with CS-
NCs. After 18  h of incubation, the cells were lysed and 
the mRNA sequenced. CS-NCs did not alter cell viability 
over an incubation period of 5 days (Additional file 1: Fig. 
S1). Detailed descriptions of our data processing, qual-
ity control analysis, and statistical modeling are available 
in the Methods section. We used a low-dose of NCs to 
mimic realistic doses of Mφ exposure in vivo and to avoid 
any response due to a high number of particles [37]. We 
identified 242 genes for which the expression was mod-
ulated by CS-NCs (FDR < 0.05, Fig.  3a and Additional 
file 2: Table S1). The expression of 156 genes was upregu-
lated and that of 86 downregulated upon treatment. In 
particular, the expression of inflammation-related genes 
(IL-12B, IL-32, TNF-α and IL-6) and that of chemokines 
(CCL20, CCL4L2, CXCL8/IL-8, and CCL4) was strongly 
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upregulated in the presence of chitosan. We examined 
a selected panel of genes to validate our transcriptomic 
data. We used ELISA to confirm the upregulation of 
TNF-α, interleukin 8 (CXCL8/IL-8), and CCL4 secretion 
in the supernatant of Μφs treated with various concen-
trations of NPs for 18 h (Fig. 3b).
We then classified the modulated genes on the basis of 
the annotation resources provided by KEGG [38] by per-
forming gene-set enrichment analysis of the list of differ-
entially expressed genes using the EnrichR tool [39]. The 
gene set differentially expressed by CS-NCs was signifi-
cantly enriched for genes involved in cytokine–cytokine 
receptor interactions (p = 4.49E−20), TNF and NF-kB 
signaling (p = 1.59E−13 and 5.33E−11, respectively), 
chemokine signaling (p = 6.28E−11), and the TLR/NLR 
pathways (p = 2.86E−10 and 9.34E−10, respectively) 
(Fig. 3c and Additional file 3: Table S2). Chitosan is a nat-
urally occurring polysaccharide derived from chitin, the 
second most common polysaccharide in nature. It is less 
common than chitin and can be found in certain species 
of fungi, but neither are expressed in mammals [40]. It 
is thus not surprising that this polysaccharide induces a 
pro-inflammatory response. Indeed, highly purified chi-
tosan was shown to potently activate the NLRP3 inflam-
masome, increasing expression of the pro-inflammatory 
cytokine IL-1β [41]. CS-NCs induced expression of pro-
inflammatory cytokines by human peripheral blood mon-
onuclear cells, including IL-6, TNF-α and IFN-γ, among 
others [35]. In vivo, chitosan has been reported to induce 
an acute inflammatory response [42] and Mφ nitric 
oxide production and chemotaxis [43]. The ability of 
CS-NCs to promote inflammation could be useful when 
drug delivery is combined with immunotherapy to elicit 
innate and adaptive immune responses against pathogens 
[44] or tumor cells [45]. However, long-term inflamma-
tory responses could be detrimental to the host. We thus 
decided to modify CS-NCs in order to decrease their 
pro-inflammatory properties, and we generated CS-NCs 
containing tri-mannose motifs. Mφs express numerous 
lectins which can bind mannose, including the mannose 
receptor and DC-SIGN [46]. These receptors have immu-
nomodulatory properties and can dampen inflammation 
upon ligand binding [47–49]. Targeting these receptors 
may thus be an attractive strategy to modulate the host 
response to CS-NCs.
Fabrication and characterization of tri‑mannose‑chitosan 
NCs
The general procedure for ligand grafting on chitosan 
surfaces, using the homobifunctional crosslinker, 
bis(sulfosuccinimidyl) suberate  (BS3), has been 
reported previously for other types of ligands [18]. 
Here, we adapted it for the linking of a tri-mannose 
ligand with an alkyl spacer chain and a primary amino 
group on the NC surface available for the reaction with 
the crosslinker (Fig. 4a and Additional file 4: Fig. S2a). 
We assessed the physicochemical properties of CS-NCs 
before and after grafting with tri-mannose. CS-NCs 
had a slightly higher mean diameter after the grafting 
process (Additional file  5: Table  S3). The tri-mannose 
chain might strongly interact with the water of the 
medium, altering its structure and organizing the sur-
rounding water molecules in a thicker hydration shell. 
In the case of Nile Red-labelled NCs, the non-grafted 
carriers were slightly less stable and their diameter 
appeared to be higher. After grafting, both labelled and 
non-labelled carriers had a hydrodynamic diameter of 
slightly less than 200 nm.
We next analyzed the morphology of the grafted NCs 
by cryo-electron microscopy. The NCs were homogene-
ous and the size of most of the spherical NCs present 
were in accordance with the dynamic light scattering 
analysis (Fig.  4b). The surface of the NCs showed no 
appreciable differences in morphology by electron 
microscopy after grafting. Nonetheless, we evaluated 
the outcome of the grafting process by Fourier transform 
infrared spectroscopy (FTIR) and by measuring the sur-
face potential of NCs before and after grafting with the 
tri-mannose ligand (Additional file 4: Fig. S2b and Addi-
tional file 5: Table S3). Unmodified chitosan surfaces gen-
erally present high positive Z potential values in water 
and slightly acidic pH, due to the presence of proto-
nated amino groups. After grafting with the tri-mannose 
ligand, the masking effect on the amino groups on the 
surface led to negative potential values. The high absolute 
values also indicated good colloidal stability of the sam-
ples under the measuring conditions.
Finally, we tested the surface availability of tri-mannose 
motifs using concanavalin A (ConA). ConA is a lectin 
that presents a tetrameric structure at physiological pH 
(7.4), formed by four identical subunits, each possess-
ing a mannose-binding site. Because of this characteris-
tic, ConA can be used as a bridge to produce a specific 
concentration-dependent, aggregate of grafted NCs that 
can be measured by DLS analysis. There was a slight sta-
bilizing effect at low concentrations of the lectin, whereas 
there was a four-fold increase in diameter at concentra-
tions above 2 nmol/mgNC (Fig. 4c). The same experiment 
was carried out using non-grafted CS-NCs and there was 
no specific aggregation (Additional file  4: Fig. S2c). We 
observed a completely different behavior of non-grafted 
NCs in the presence of buffer only, showing, in this case, 
an important aggregation effect due to the presence of 
salt. Comparison of the results obtained with grafted 
and non-grafted NCs further demonstrate the effi-
cacy of the grafting process on the chitosan surface and 
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demonstrates the availability of the ligand for the affinity 
interaction with lectin receptors.
Tri‑mannose grafting dampens the response of Mφs 
to CS‑NCs
We first evaluated whether the addition of tri-mannose 
ligands to the surface of the NCs would improve their 
uptake by Mφs , as this cell type expresses several lectins 
at high levels, including the mannose receptor. There 
were no significant differences in internalization between 
NCs, with or without tri-mannose ligands (Fig.  5a). We 
obtained similar results with other cell types, such as 
A549 epithelial cells and HepG2 hepatocytes (Additional 
file  6: Fig. S3a). As for CS-NCs, the entry of CS-NCs 
b
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Fig. 4 Morphological characterization of tri‑mannose‑grafted chitosan NCs. a Schematic representation of a mannosylated CS‑NC. b CryoTEM 
image of CS‑NCs‑tri. c Hydrodynamic diameter of CS‑NCs‑tri incubated at various concentrations of concanavalin A, assessed by dynamic light 
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grafted with tri-mannose motifs, hereafter designated 
CS-NCs-tri, was cytochalasin D-dependent, suggesting a 
phagocytic process (Additional file 6: Fig. S3b, Additional 
file 7: Fig. S4).
We next compared the Mφ response to CS-NCs and 
CS-NCs-tri. In resting Mφs , both nanocarriers modu-
lated the expression of relatively few genes relative to 
other stimuli, such as LPS, in which more than 2500 
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genes have been described to be differentially expressed 
(Figs. 3a, 5b) [50]. We identified only 242 and 159 genes 
differentially expressed by cells upon treatment with 
respectively CS-NCs and CS-NCs-tri, of which 105 were 
in common (Fig. 5b and Additional file 8: Table S4). The 
expression of 42% of the genes differentially expressed 
upon treatment with CS-NCs-tri was upregulated. 
We first focused our analysis on the genes in common 
between the two nanocarriers. Unfortunately, the graft-
ing of tri-mannose failed to decrease the pro-inflamma-
tory properties of chitosan. The expression of the potent 
inflammatory mediators, TNF-α and IL-6, and several 
chemokines reported to attract immune effector cells 
(monocytes, neutrophils, dendritic cells, and activated 
T cells) was upregulated in the presence of both nano-
particles (Fig. 5c). Modulated genes were then classified 
based on the annotation resources provided by GeneOn-
tology. The set of genes upregulated by NCs was signifi-
cantly enriched for genes involved in immune activation, 
such as inflammatory response (p = 9.65E−15), neutro-
phil chemotaxis (p = 7.79E−1), and the cellular response 
to IL-1 (p = 7.48E−10) (Fig.  5d and Additional file  9: 
Table  S5). The shared response between CS-NCs and 
CS-NCs-tri most likely reflects the recognition of chi-
tosan by Mφs as a pathogen-associated molecular pattern 
(PAMP), as described above.
We then evaluated the impact of tri-mannose graft-
ing on the Mφ response by analyzing the differentially 
expressed genes specific of each nanocarrier. Functional 
classification of the 137 genes differentially regulated by 
only ungrafted CS-NCs showed that the type I-interferon 
(IFN-I) signaling pathway was the most significantly 
upregulated (Fig. 5e and Additional file 10: Table S6). This 
pathway comprised IL1A, SOCS3, CSF3, RSAD2, OAS2, 
MX1, IFI6, IRF, GP1BA, and EREG. Type I-IFNs play a 
key role in the antiviral response and are also involved 
in autoimmunity (lupus and genetically based interfer-
onopathies) [51], cancer [52], and the immune escape 
mechanisms of bacterial pathogens, such as Mycobac-
terium tuberculosis [53]. Indeed, blood transcriptional 
profiling in TB patients, non-human primates, and mice 
infected with M. tuberculosis have shown up-regulation 
of type I-IFN response related genes, and type I-IFN was 
associated with impaired control of bacterial growth and 
elevated pulmonary immunopathology in murine mod-
els of tuberculosis [54]. Similar results were obtained 
with other bacteria, such as Listeria monocytogenes, 
Brucella abortus, and Staphylococcus aureus [55, 56]. 
In the context of bacterial infections, CS-NCs-tri may 
offer the advantage of boosting the immune response 
while avoiding prolonged IFN-I signaling, which leads 
to immune dysfunction and bacterial escape. Note that 
functional classification of the 54 genes regulated by 
only CS-NCs-tri did not permit to identify significant 
pathways, probably because of too few differentially-
expressed genes.
Tri‑mannose modulates the response of M. 
tuberculosis‑infected Mφs
Bacterial infection induces important remodeling of the 
infected cell transcriptome [57]. Nanoparticles may thus 
affect uninfected and infected cells in a different man-
ner. We evaluated the impact of the two types of NCs 
on the response of bacteria-infected Mφs . We used a 
similar approach as described above. Briefly, Mφs were 
infected with a virulent strain of M. tuberculosis and then 
treated with CS-NCs or CS-NCs-tri. After 18 h of incu-
bation, the cell transcriptome was analyzed by mRNA 
sequencing. There was no difference in the uptake of 
NCs between naïve and infected cells (Fig.  6a). Unex-
pectedly, the treatment of M. tuberculosis-infected Mφs 
with CS-NCs-tri induced significant remodeling of the 
cell transcriptome. Overall, 958 genes were differentially 
expressed in cells incubated with CS-NCs-tri, whereas 
only 120 were differentially expressed in CS-NCs treated 
cells (Fig.  6b and Additional file  11: Table  S7). Among 
the 958 genes, 873 were specific to CS-NCs-tri and the 
expression of most were downregulated (67%, Fig.  6c). 
The set of genes specifically modulated by CS-NCs-tri 
was enriched for genes involved in oxidative phosphoryl-
ation (up-regulation, p = 4.73E−11), metabolic pathways 
(p = 1.23E−06), and sugar metabolism (downregulation, 
p = 2.16E−3) (Fig.  6d and Additional file  12: Table  S8). 
These results suggest that tri-mannose grafting affect the 
mitochondrial machinery and remodel cellular metabo-
lism. Metabolic signaling dictates the fates and functions 
of many cell types, including T lymphocytes, B cells, and 
Mφs . For example, Mφs can be schematically classified 
into two main classes, depending on their activation sta-
tus: inflammatory or M1 Mφs , and alternatively activated 
M2 Mφs , involved in wound healing and angiogenesis. 
It has been shown that M2 polarization is dependent on 
fatty acid oxidation and oxidative phosphorylation [58, 
59]. Tri-mannose ligands may thus favor M2 polarization 
in the context of bacterial infection.
Conclusions
Here we dissected in detail the response of human 
Mφs to two chitosan-based NCs, containing tri-
mannose motifs at their surface or not. We identi-
fied a core response to both NCs, mainly associated 
with innate immune cell activation. We also detected 
unique pathways to CS-NCs and CS-NCs-tri. Some 
pathways, such as that of type I-IFN, have been shown 
to be exploited by certain pathogens to escape the 
immune response. It would thus be very informative to 
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evaluate whether such NCs can hinder such pathogen 
strategies. Our study also showed that grafting NCs 
with tri-mannose can remodel the transcriptome of M. 
tuberculosis-infected cells, in particular affecting the 
regulation of many metabolic pathways. Further exper-
iments will allow gaining insights into the mechanisms 
and consequences of cell metabolism modulation by 
tri-mannose grafting. The possibility to modulate cell 
metabolism by grafting ligands to the surface of the 
nanoparticles offers new perspectives. Indeed, many 
diseases, including infectious diseases, are associated 
with metabolic dysfunction. The grafting of nanopar-
ticles with metabolic modulators in adjunction to con-
ventional drugs may thus be a promising strategy to 
treat such diseases.
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Methods
Materials
All reagents were purchased from Sigma-Aldrich 
unless otherwise specified.  Tween® 20 and absolute 
EtOH were purchased from Panreac Química S.L.U. 
Bis(sulfosuccinimidyl) suberate  (BS3) was purchased 
from Pierce Biotechnology Inc. and 4-aminobutyl 
2-O-(a-d-mannopyranosyl) 2-O-(a-d-mannopyranosyl) 
a-d-mannopyranoside was purchased from Omicron 
Biochemicals Inc.
Macrophages and cell lines
Blood mononuclear cells were isolated by Ficoll-Paque 
centrifugation (GE Healthcare Life Sciences).  CD14+ 
monocytes were isolated by positive selection using 
CD14 microbeads (Miltenyi Biotec) and allowed to dif-
ferentiate into Mφs in the presence of RPMI 1640 supple-
mented with 10% fetal bovine serum, 2  mM Glutamine 
and granulocyte–macrophage colony-stimulating factor 
(GM-CSF) (20 ng/ml; R&D Systems) over a 6-day period 
(hereafter defined as cell culture medium). Cell cultures 
were fed every 2 days. Human lung epithelium A549 cells 
(Sigma) were cultured in MEM. Human Hep G2 hepato-
cytes (Sigma) were cultured in EMEM (EBSS) supple-
mented with 10% fetal bovine serum, 2  mM Glutamine 
and 1% non-essential amino acids. Cultures were incu-
bated at 37 °C in 5%  CO2.
CS‑NC synthesis
CS-NCs were prepared as previously described [18]. For 
fluorescently labelled NCs, 100 μg Nile Red fluorophore 
was added to 40  ml organic phase before adding this 
solution to the aqueous phase for nanoemulsion forma-
tion. After 15  min, chitosan was added to stabilize the 
nanoemulsion. Finally, the chitosan-coated nanoemul-
sion was added to 200 ml 50 mM  Na2SO4. Capsules were 
separated from  Na2SO4 by ultracentrifugation (30  min, 
69,673 × G, 10  °C), washed with 100  mL water, centri-
fuged again, and resuspended in water. The endotoxin 
concentration was < 0.05 EU.
Flow cytometry
CS-NCs were labeled by encapsulation of Nile Red. 
Mφs , epithelial cells, and hepatocytes (4 × 105 cells/
ml) were grown on 24-well plates for 24  h in cell cul-
ture medium, followed by 1 to 18  h of treatment with 
various concentrations of fluorescent NCs. After incuba-
tion, cells were extensively washed with PBS to remove 
extracellular NCs, harvested, and resuspended in 4% 
paraformaldehyde for analysis using a CytoFLEX flow 
cytometer (Beckman Coulter). When indicated, cells 
were preincubated for 1 h with inhibitors in serum-free 
RPMI medium. The media was then changed to cell cul-
ture medium containing inhibitors plus fluorescent par-
ticles (100 μg/ml) and further incubated for 2 h. NC-only 
treated cells were used as positive controls and compared 
to inhibitor plus NC-treated cells. Concentrations were 
obtained from the literature for chlorpromazine (10 μg/
ml), colchicine (2 μg/ml), cytochalasin D (10 μg/ml), and 
nystatin (20  μg/ml). All inhibitors were obtained from 
Sigma-Aldrich. More than 10,000 events per sample 
were recorded. The analysis was performed using FlowJo 
software.
Confocal microscopy
Mφs (4 × 105 cells/ml) were grown on 12-mm circu-
lar coverslips in 24-well tissue culture plates for 24 h in 
cell culture medium, followed by 1, 4 and 18 h of treat-
ment with 100  μg/ml fluorescent NCs. Cells were then 
extensively washed with PBS and subsequently stained 
when indicated for 1  h with 1  mM  LysoTracker® Red 
DND-99 (ThermoFisher Scientific), following the manu-
facturer’s protocol. Cells were then washed twice with 
PBS, fixed with 4% paraformaldehyde for 30  min at RT, 
and mounted on a glass slide using Fluoromount mount-
ing medium containing 1  µg/ml 4′,6-diamidino-2-phe-
nylindole (DAPI) (Invitrogen). Cells were analyzed with 
a Leica TCS SP2 Confocal System. Z-stack optical sec-
tions were acquired at 0.3-µm-depth increments. Decon-
volution and alignment of complete image stacks was 
performed with Huygens Pro (version 14.10, Scientific 
Volume Imaging). Each cell was analyzed with “Colocali-
zation Analyzer” module to get quantitative information 
about the amount of spatial overlap between NCs and 
 LysoTracker® in data channels.
Transmission electron microscopy (TEM)
The intracellular localization of CS-NCs in Mφs was 
assessed by TEM. Cells incubated with 100  μg/ml NCs 
were fixed with 4% glutaraldehyde in 0.2 M sodium caco-
dylate pH 7 for 2 h at 4  °C. The cells were then washed 
twice with PBS and resuspended in 1 ml of 0.1% glutaral-
dehyde. Resin blocks were cut into 50-nm slices using an 
ultramicrotome. Samples were observed in a FEI Tecnai 
T20 microscope operating at 200 kV.
Cytotoxicity assay
Mφs (0.1 × 106 cells/well) were grown in 96-well plates 
for 24 h, followed by treatment with various concentra-
tions of NCs for the indicated times. Cell viability was 
determined by MTT assay following the manufacturer’s 
protocol (Trevigen).
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RNA isolation, library preparation, and sequencing
Total RNA from macrophages was extracted using QIA-
zol reagent (Life Technologies) and purified over RNeasy 
columns (Qiagen). The quality of all samples was assessed 
with an Agilent 2100 bioanalyzer (Agilent Technolo-
gies) to verify RNA integrity. Only samples with a good 
RNA yield and no RNA degradation (ratio of 28S to 18S, 
> 1.7; RNA integrity number > 9) were used for further 
experiments. cDNA libraries were prepared with the Illu-
mina TruSeq RNA Sample Preparation Kit v2 and were 
sequenced on an llumina HiSeq 2500 at the CHU Sainte-
Justine Integrated Centre for Pediatric Clinical Genomics 
(Montreal, Canada). STAR v2.5.0b [60] was used to map 
RNA-seq reads to the hg38 reference genome and quan-
tify gene expression (option-quantMode GeneCounts) by 
counting the fragments overlapping the Ensembl genes 
(GRCh38 v. 83). Differential expression analysis was per-
formed using a generalized linear model with the R Bio-
conductor package edgeR v3.16.5 [61] on the genes with 
more than one count per million (CPM) in at least two 
samples. The model formula used in edgeR (~ Donor + I 
nfe cti o n +  Inf ect ion:Donor + Infection:Treatment + D
onor:Treatment) contained: the main effects for Donor 
and Infection, interactions of Donor with Infection and 
Treatment to adjust for various responses to infection 
and treatment between donors, and a nested interaction 
of Infection with Treatment because we were interested 
in the infection-status-specific treatment effects. The 
latter was used to extract differentially expressed genes 
between NC-treated and untreated samples under the 
infected and uninfected conditions.
Mycobacteria and Mφ infection
Mycobacterium tuberculosis H37Rv was grown from 
a frozen stock to mid-log phase in 7H9 medium (Bec-
ton–Dickinson), supplemented with albumin–dextrose–
catalase (ADC, Difco), and Mφ infection carried out 
as previously described [62]. Before infection, bacteria 
were washed three times and re-suspended in 1 ml PBS. 
Clumps were dissociated by 30 passages through a nee-
dle and then allowed to sediment for 5 min. The density 
of bacteria in the supernatant was verified by measur-
ing the  OD600 and aliquot volumes defined to allow one 
bacterium-per two cell infections. Cells were infected in 
24-well plates with each well containing 0.5 × 106 cells in 
1 ml medium containing GM-CSF (R&D Systems). After 
2  h of incubation at 37  °C, infected cells were washed 
three times in PBS to remove extracellular bacteria and 
incubated in fresh medium. M. tuberculosis strain H37Rv, 
expressing green-fluorescent protein (GFP) (GFP-M. 
tuberculosis), carried the pEGFP plasmid (gift from G. 
Stewart, Imperial College, London, U.K.), which encodes 
resistance to hygromycin and harbors the gfp gene under 
the control of the mycobacterial Phsp60 constitutive 
promoter.
Enzyme‑linked immunosorbent assay (ELISA)
At 18  h after NC treatment, supernatants from treated 
and untreated macrophages were filtered (pore size, 
0.22  μm; Millipore). Levels of TNF-α, IL-8, and CCL4 
(R&D) were determined in triplicate by ELISA following 
the protocol of the assay kit manufacturers.
Tri‑mannose‑CS‑NC synthesis and characterization
NCs (20  mg) were diluted in 10  mM borate buffer pH 
8.2 for grafting with tri-mannose ligand. First, 50  nmol 
 BS3 crosslinker was added for each mg of NCs and the 
reaction incubated for 30  min under stirring at room 
temperature. Then, a fourfold excess of 4-aminobutyl 
2-O-(a-d-mannopyranosyl) 2-O-(a-d-mannopyranosyl) 
a-d-mannopyranoside, corresponding to a total amount 
of 4 μmoles of tri-mannose ligand, was added and the 
reaction mixture incubated for 2  h under stirring at 
40 °C. Finally, an excess of 50 mM TRIS–HCl buffer pH 
8.2 was added to quench any unreacted linker. Grafted 
NCs were washed three times, including centrifugation 
for 1  h at 16,000  rpm and 4  °C, to separate them from 
residual reactants. The NC concentration in a water sus-
pension was obtained by measuring the weight of a fixed 
volume of sample after freeze-drying. The hydrodynamic 
diameter and polydispersity index (PDI) of the NCs were 
measured by dynamic light scattering analysis using a 
Brookhaven 90Plus DLS instrument and the Photo-Cor-
relation Spectroscopy (PCS) technique. The endotoxin 
concentration was < 0.05 EU.
Cryogenic transmission electron microscopy
Specimens were vitrified in liquid ethane and analyzed in 
a TEM microscope at low temperature. The vitrification 
process was performed in an FEI Vitrobot: a 3-µl drop of 
an aqueous suspension of the material was placed on a 
TEM Quantifoil carbon grid, excess water blotted away at 
the Vitrobot with filter paper, and the grid freeze-plunged 
into liquid ethane. Samples were then transferred under a 
liquid nitrogen atmosphere to a Gatan TEM cryo-holder 
equipped with a liquid nitrogen reservoir. TEM images 
were obtained in a Tecnai T20 (FEI), operated at 200 kV, 
coupled to a Veleta CCD camera.
Determination of the surface potential
The surface potential was measured using a Plus Particle 
Size Analyzer (Brookhaven Instruments Corporation). 
NCs were analyzed in a 1 mM KCl suspension at a con-
centration of 0.01 mg/ml of material.
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Fourier transform infrared spectroscopy analysis
A JASCO FT/IR—4100 Fourier transform infrared 
spectrometer in a frequency range of 600–4000  cm−1 
was used to carry out the analysis using a resolution of 
2 cm−1 and a scanning number of 32.
Concanavalin A aggregation test
NCs were diluted in 10 mM TRIS–HCl buffer pH 7.4 at 
a concentration of 0.2  mg/ml and various amounts of 
concanavalin A (0.5 to 8 nmol/mgNC) added. The mix-
ture was left for 120  min for the interaction to occur 
and the degree of aggregation was subsequently meas-
ured by determining the hydrodynamic diameter of the 
NCs.
Statistical analysis
Means were analyzed by 1-way ANOVA or the unpaired 
two tailed Student’s t test, for which p values < 0.05 
(*), < 0.01 (**), and < 0.001 (***) were considered to be sta-
tistically significant. Analyses were performed using the 
Prism 5 program for MAC OS X (GradhPad Software). 
p-values for the RNA sequencing data were adjusted for 
multiple comparisons using the Benjamini–Hochberg 
method, producing an adjusted p-value or false-discovery 
rate (FDR). An FDR < 0.05 was considered to be statisti-
cally significant.
Additional files
Additional file 1: Fig. S1. Cytotoxicity of chitosan NCs. M φ s were 
exposed to 100 µg/ml CS‑NC for 18 h and 5 days. Cell viability was meas‑
ured by the MTT assay.
Additional file 2: Table S1. Differentially‑expressed genes by M φ s upon 
chitosan NC treatment. FDR < 0.05.
Additional file 3: Table S2. KEGG enrichment of differentially expressed 
genes upon chitosan NC treatment. p‑value < 0.05.
Additional file 4: Fig. S2. Physicochemical and biological properties of 
tri‑mannose‑grafted chitosan NCs. a Chemical structure of the chitosan, 
BS3 linker, and trimannoside used to perform the grafted NCs. b FTIR 
analysis of CS‑NCs before and after grafting with tri‑mannose ligands. c 
Hydrodynamic diameter of non‑grafted CS‑NCs incubated with various 
concentrations of concanavalin A.
Additional file 5: Table S3. Dynamic light scattering and Z‑potential 
analysis. NCs were characterized in terms of size (hydrodynamic diameter), 
polydispersity index (PDI), and surface potential (Z‑potential).
Additional file 6: Fig. S3. Cellular uptake of tri‑mannose‑grafted chitosan 
NCs. a 100 µg/ml of Nile‑Red‑labelled CS‑NCs‑tri were incubated for 4 h 
with M φ s, A549 epithelial cells, or HepG2 hepatocytes. NP uptake was 
analyzed by FACS as mentioned above. b M φ s were incubated with 
100 µg/ml fluorescent NCs for 2 h with or without nystatin, colchicine, 
cytochalasin D, or chlorpromazine. NC uptake was analyzed by FACS.
Additional file 7: Fig. S4. TEM micrographs of internalized tri‑mannose‑
grafted chitosan NCs. M φ s were cultured for 1 a or 18 h. b in the presence 
of 100 µg/ml CS‑NCs‑tri. Intracellular localization was then assessed 
by TEM. Yellow arrows: CS‑NCs, Red arrows: NCs fusion. Note that NC 
fusion leads to the formation of big nanoparticles in some cells at 18 h 
post‑treatment.
Additional file 8: Table S4. Differentially expressed genes by M φ s upon 
tri‑mannose‑grafted chitosan NC treatment. First table: all genes differen‑
tially expressed. Second table: genes modulated by both NCs. Third table: 
genes modulated only by CS‑NCs‑tri. FDR < 0.05.
Additional file 9: Table S5. GO enrichment of genes differentially 
expressed by both chitosan NCs and tri‑mannose‑grafted chitosan NCs. 
p‑value < 0.05.
Additional file 10: Table S6. GO enrichment of genes differentially 
expressed only upon treatment with chitosan NCs. p‑value < 0.05.
Additional file 11: Table S7. Genes differentially expressed by M. tubercu-
losis infected M φ s upon treatment with NCs. First table: genes modulated 
by CS‑NCs. Second table: genes modulated by CS‑NCs‑tri. FDR < 0.05.
Additional file 12: Table S8. KEGG enrichment of genes differentially 
expressed by M. tuberculosis infected M φ s upon treatment with tri‑man‑
nose‑grafted chitosan NCs. First table: up‑regulated processes. Second 
table: down‑regulated processes. p‑value < 0.05.
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